PD-1 inhibition in sarcoma still needs investigation

PD-1 inhibition in sarcoma still needs investigation.

The Lancet Oncology, Jan 2018

Toulmonde M, Italiano A.

doi: 10.1016/S1470-2045(17)30921-X

https://www.ncbi.nlm.nih.gov/pubmed/29304365

Comment in

• PD-1 inhibition in sarcoma still needs investigation – Authors’ reply.[Lancet Oncol. 2018]

Comment on

• Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.[Lancet Oncol. 2017]